Pfizer is a general drug manufacturer company located in New York, United States, which is part of the Healthcare sector, and is traded under the ticker PFE on the NYSE exchange.
Pfizer stock last closed at $44.06, down 0.63% from the previous day, and has decreased 17.46% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.3 percentage points. Pfizer stock is currently +6.31% from its 52-week low of $41.45, and -21.77% from its 52-week high of $56.32.
As of Feb 3, 2023, there are 5.61B shares of PFE outstanding. The market cap of PFE is $247.32B. In the last 24 hours, 23.73M PFE shares were traded.
You will need an online brokerage account to access the NYSE market and buy PFE stock.
We believe that eToro is the best brokerage. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro today.Open eToro Account
Now that you've picked your brokerage, you'll need to fill out some personal info so you are able to invest in PFE today.
Now that you have filled out your info on one of the most highly reviewed stock trading apps, you can securely and quickly fund your account:
Watch the walkthrough below for more details transferring funds into your new investment account.
After you have figured out the best place to buy Pfizer stock, it's very important to research their stock prior to investing, so you truly understand the risk as well as the upside.
WallStreetZen was created to help everyday investors do more accurate fundamental analysis.
You can view all of the due diligence checks on PFE's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge PFE's intrinsic value.
Using relative valuations metrics:
You can do more valuation research on PFE's stock here.
Out of 13 Wall Street analysts who give forecasts on PFE, the consensus analyst rating on Pfizer is a Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
Terence Flynn, a top 26% analyst from Morgan Stanley maintains PFE with a hold rating and lowers their PFE price target from $53.00 to $45.00, on Feb 1, 2023.
Louise Chen, a bottom 4% analyst from Cantor Fitzgerald reiterates PFE with a strong buy rating and maintains their PFE price target from $75.00 to $75.00, on Feb 1, 2023.
Trung Huynh, a bottom 19% analyst from Credit Suisse maintains PFE with a buy rating and lowers their PFE price target from $54.00 to $50.00, on Feb 1, 2023.
Evan David Seigerman, a top 46% analyst from BMO Capital maintains PFE with a buy rating and lowers their PFE price target from $55.00 to $53.00, on Feb 1, 2023.
Carter Gould, a bottom 8% analyst from Barclays maintains PFE with a hold rating and lowers their PFE price target from $49.00 to $44.00, on Feb 1, 2023.
Gould lowered his price target on Pfizer Inc. by 10.2% following the release of the company's Q4 and FY 2022 earnings report on 2023/01/31.
The analyst reported that he reduced his FY 2023 COVID-related sales estimates post-print.
"The greater risk continues to be to the downside with the end of the public health emergency on the horizon," Gould advised.
He "sees a difficult setup to underwrite rising demand versus current levels," the analyst concluded.
For Q4 2022:
For FY 2022:
For FY 2023, management guided:
Pfizer shares have lost 15% of their value YTD against the S&P 500's 4.6% gain.
Chairman & CEO Dr. Albert Bourla commented: "As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we’ve ever had in such a short period of time.
"We believe that the combination of these expected near-term launches, additional pipeline products that could potentially come to market in the medium-term, and anticipated contributions from business development, has the potential to set the company up for continued robust growth through the rest of this decade and beyond.”
You can dive deeper into what analysts are forecasting on the Pfizer stock forecast page.
Last year, PFE earnings were $29.77B. In the last 5 year, PFE's earnings have gone up by 26.49% per year. This was faster than the Drug Manufacturers - General industry average of 12.86%.
Last year, PFE revenue was $99.68B. In the last five year, PFE's revenue has grown by 13.69% per year. This was faster than the Drug Manufacturers - General industry average of 8.23%.
Find out more about PFE's earnings and revenue performance here.
Over the past 12 months, insiders at PFE have bought more shares than they have sold.
Albert Bourla, Chairman CEO of PFE, was the latest PFE insider to buy. They bought $4,017,799.24 worth of PFE shares on Dec 16, 2022.
Dig into more about who owns PFE shares here.
Pfizer pays a dividend of 3.65%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.19%. If you owned $1,000 of PFE stock, you would have received $36.54 in the past 12 months.
Pfizer dividend payments have consistently grown over the past decade and have remained stable.
Get more data about Pfizer dividend yield and history here.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
There are two main types of orders:
Click the Open button and your broker will execute the order.
If you need more assistance investing in stocks on eToro, click the how to video below:
Now that you own some PFE stock, you'll want to keep up with your new investment.
Create a watchlist to keep track of your PFE stock.
To reiterate, here are the 6 steps to buy Pfizer stock:
If you require a brokerage, eToro is our recommended option.Get Started with eToro Today
If you would like to get updates on your investment in Pfizer, add PFE to your watchlist by clicking the button below.
How much does it cost to buy one Pfizer share?
Is now a good time to buy Pfizer stock?
What is the best way to buy Pfizer stock?